Survivin Expression Can Predict the Effect of Chemoradiotherapy for Advanced Lower Rectal Cancer

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2012 Sep 1

PMID 22936565

Citations 3

Authors

Chie Takasu

Mitsuo Shimada

Nobuhiro Kurita

Takashi Iwata

Hirohiko Sato

Masanori Nishioka

Shinya Morimoto

Kozo Yoshikawa

Tomohiko Miyatani

Hideya Kashihara

Tohru Utsunomiya

Hisanori Uehara

Affiliations

Soon will be listed here.

Abstract

Background: Chemoradiotherapy (CRT) has been used to improve local control and survival in patients with advanced rectal carcinoma. However, a significant proportion of patients show poor response to adjuvant CRT. We thus investigated the usefulness of survivin expression as a predictive marker of the CRT response and its characteristics.

Methods: Forty-three patients with lower rectal cancer who underwent CRT were investigated. All patients received preoperative CRT consisting of TS-1 concurrent with 40 Gy of pelvic irradiation followed by curative resection. The relationship between clinical response, or pathological response, and the expression of survivin of pre-CRT biopsy specimens was evaluated by immunohistochemistry and compared with post-CRT expression.

Results: Positive expression of survivin was observed in 26 of 43 patients (60%) in pre-CRT specimens. Survivin was positively expressed in 77% of stable disease cases, and 43% of partial response (p < 0.05). Regarding the correlation between pathological response and survivin expression, positive expression of survivin was recognized in 75% (18 of 24) of Grade 0 + 1 cases, 50% (7 of 14) of Grade 2 cases, and 20% (1 of 5) of Grade 3 cases. A reverse correlation was recognized between pathological responses and survivin expression (p < 0.05). There were differences in the tumor differentiation between the survivin-positive group and the negative group (p < 0.05). The expression concordance rate was 66% between pre- and post-CRT tissues. In post-CRT tissues, nuclear survivin expression disappeared completely and cytoplasmic expression increased, especially in responder cases.

Conclusion: Survivin expression in biopsy could be an important predictive factor of preoperative CRT response.

Citing Articles

Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Takasu C, Nishi M, Yoshikawa K, Tokunaga T, Nakao T, Kashihara H BMC Cancer. 2022; 22(1):1263.

PMID: 36471264 PMC: 9720962. DOI: 10.1186/s12885-022-10357-1.

Monitoring survivin expression in cancer: implications for prognosis and therapy.

Guindalini R, Mathias Machado M, Garicochea B Mol Diagn Ther. 2013; 17(6):331-42.

PMID: 23912862 DOI: 10.1007/s40291-013-0048-1.

Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis.

Krieg A, Werner T, Verde P, Stoecklein N, Knoefel W PLoS One. 2013; 8(6):e65338.

PMID: 23755220 PMC: 3670901. DOI: 10.1371/journal.pone.0065338.

References

Holm T, Cedermark B, Rutqvist L . Local recurrence of rectal adenocarcinoma after 'curative' surgery with and without preoperative radiotherapy. Br J Surg. 1994; 81(3):452-5. DOI: 10.1002/bjs.1800810344. View

Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T . Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005; 65(11):4881-7. DOI: 10.1158/0008-5472.CAN-04-3028. View

Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D . Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery. 2005; 138(2):299-305. DOI: 10.1016/j.surg.2005.05.009. View

Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K . Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996; 7(5):548-57. DOI: 10.1097/00001813-199607000-00010. View

Koda K, Saito N, Ochia T, Miyazaki M, Sarashina H, Nakajima N . Randomized, controlled study of continuous 5-FU infusion starting immediately after curative surgery for advanced colorectal cancer. Hepatogastroenterology. 2009; 56(89):116-9. View

Spiliotis J, Datsis A . The surgical approach to locally recurrent rectal cancer. Tech Coloproctol. 2005; 8 Suppl 1:s33-5. DOI: 10.1007/s10151-004-0105-1. View

Sadahiro S, Suzuki T, Maeda Y, Tanaka Y, Nakamura T, Saguchi T . Predictors of tumor downsizing and regression with preoperative radiotherapy alone and with concomitant tegafur/uracil (UFT) for resectable advanced rectal adenocarcinoma. Hepatogastroenterology. 2007; 54(76):1107-12. View

Capalbo G, Dittmann K, Weiss C, Reichert S, Hausmann E, Rodel C . Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int J Radiat Oncol Biol Phys. 2010; 77(1):226-34. DOI: 10.1016/j.ijrobp.2009.12.001. View

Peltenburg L . Radiosensitivity of tumor cells. Oncogenes and apoptosis. Q J Nucl Med. 2001; 44(4):355-64. View

10.

Shivnani A, Small Jr W, Stryker S, Kiel K, Lim S, Halverson A . Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg. 2007; 193(3):389-93. DOI: 10.1016/j.amjsurg.2006.09.030. View

11.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

12.

Gudkov A, Komarova E . The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003; 3(2):117-29. DOI: 10.1038/nrc992. View

13.

Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A . Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996; 56(11):2602-6. View

14.

Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T . Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001; 91(11):2026-32. DOI: 10.1002/1097-0142(20010601)91:11<2026::aid-cncr1228>3.0.co;2-e. View

15.

Han N, Galandiuk S . Induction chemoradiation for rectal cancer. Arch Surg. 2006; 141(12):1246-52. DOI: 10.1001/archsurg.141.12.1246. View

16.

Rodel F, Frey B, Leitmann W, Capalbo G, Weiss C, Rodel C . Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys. 2008; 71(1):247-55. DOI: 10.1016/j.ijrobp.2008.02.011. View

17.

Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H, Sakata Y . Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep. 2010; 24(5):1307-13. DOI: 10.3892/or_00000987. View

18.

Altieri D . Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem. 2004; 92(4):656-63. DOI: 10.1002/jcb.20140. View

19.

Li J, Xing M, Zhu M, Wang X, Wang M, Zhou S . Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett. 2008; 272(1):91-101. PMC: 2680926. DOI: 10.1016/j.canlet.2008.06.032. View

20.

Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer K . Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol. 2003; 29(4):379-82. DOI: 10.1053/ejso.2002.1415. View